Ascent Group, LLC Novo Nordisk A S Transaction History

Ascent Group, LLC

$1.29 Billion
Q3 2024

A detailed history of Ascent Group, LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Ascent Group, LLC holds 23,155 shares of NVO stock, worth $2.43 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares

23,155

Previous 22,869 1.25%

Holding current value

$2.43 Million

Previous $3.26 Million 15.53%

% of portfolio

0.21%

Previous 0.27%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$119.07 - $145.42 $34,054 - $41,590	286 Added 1.25%	23,155 $2.76 Million
Q2 2024 Aug 14, 2024	BUY	$122.71 - $146.91 $450,345 - $539,159	3,670 Added 19.12%	22,869 $3.26 Million
Q1 2024 May 15, 2024	BUY	$102.11 - $135.92 $81,177 - $108,056	795 Added 4.32%	19,199 $2.47 Million
Q4 2023 Feb 13, 2024	BUY	$87.78 - $105.45 $795,023 - $955,060	9,057 Added 96.9%	18,404 $1.9 Million
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $392,497 - $861,214	4,316 Added 85.79%	9,347 $850,000
Q2 2023 Aug 14, 2023	SELL	$155.98 - $172.65 $129,775 - $143,644	-832 Reduced 14.19%	5,031 $814,000
Q1 2023 May 10, 2023	BUY	$132.34 - $159.14 $35,202 - $42,331	266 Added 4.75%	5,863 $933,000
Q4 2022 Feb 16, 2023	SELL	$102.55 - $135.33 $13,126 - $17,322	-128 Reduced 2.24%	5,597 $757,000
Q3 2022 Nov 14, 2022	SELL	$95.28 - $116.93 $74,604 - $91,556	-783 Reduced 12.03%	5,725 $623,000
Q2 2022 Aug 05, 2022	SELL	$103.24 - $121.81 $1,032 - $1,218	-10 Reduced 0.15%	6,508 $755,000
Q1 2022 May 10, 2022	BUY	$93.1 - $112.54 $216,364 - $261,542	2,324 Added 55.41%	6,518 $724,000
Q4 2021 Mar 01, 2022	BUY	$95.88 - $117.08 $402,120 - $491,033	4,194 New	4,194 $400,000

Others Institutions Holding NVO

# of Institutions

1,954

Shares Held

320M

Call Options Held

5.49M

Put Options Held

7.78M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $237B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ascent Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ascent Group, LLC with notifications on news.

Account